NYSE: AORTArtivion Inc Stock
$41.48-1.55 (-3.6%)
Updated Jan 27, 2026
AORT Price
$41.48
Fair Value Price
N/A
Market Cap
$1.97B
52 Week Low
$21.97
52 Week High
$48.25
P/E
-180.35x
P/B
4.48x
P/S
4.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$422.65M
Earnings
-$9.14M
Gross Margin
64.5%
Operating Margin
5.31%
Profit Margin
-2.2%
Debt to Equity
0.96
Operating Cash Flow
$30M
Beta
1.04
Next Earnings
Feb 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AORT Overview
Artivion, Inc. distributes cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. The human tissues distributed by Artivion include the CryoValve SG pulmonary human heart valve and the CryoPatch SG pulmonary cardiac patch tissue, both processed using Artivion's proprietary SynerGraft technology. Artivion's medical devices consist of surgical adhesives, sealants, and hemostats, as well as On-X Heart Valves, and aortic stent-grafts. Artivion, Inc. was incorporated in 1984 and is based in Kennesaw, GA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AORT's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
AORT
Ranked#12 of 99
Ranked#12 of 99
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.08 | A | |
| $29.11 | A | |
| $7.92 | A |
Be the first to know about important AORT news, forecast changes, insider trades & much more!
AORT News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AORT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AORT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AORT is poor value based on its book value relative to its share price (4.48x), compared to the US Medical Devices industry average (3.79x)
P/B vs Industry Valuation
AORT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AORT due diligence checks available for Premium users.
Valuation
AORT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-180.35x
Industry
23.92x
Market
41.71x
AORT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.48x
Industry
3.79x
AORT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AORT's financial health
Profit margin
Revenue
$113.4M
Net Income
$6.5M
Profit Margin
5.7%
AORT's Earnings (EBIT) of $22.44M... subscribe to Premium to read more.
Interest Coverage Financials
AORT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$857.7M
Liabilities
$419.0M
Debt to equity
0.96
AORT's short-term assets ($337.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AORT's short-term assets ($337.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AORT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AORT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$22.3M
Investing
-$4.6M
Financing
$2.3M
AORT's operating cash flow ($30.46M)... subscribe to Premium to read more.
Debt Coverage Financials
AORT vs Medical Device Stocks
Artivion Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.